Glucommander Pediatrics now carries FDA Breakthrough Device Designation. The insulin dosing recommendation algorithm is built for hospitalized newborns and infants up to two years old.
No FDA-cleared insulin dosing software exists for that group. Hyperglycemia shows up often in premature and critically ill newborns, where it tracks with worse outcomes, and continuous intravenous insulin remains the standard. Insulin sits on the high-alert medication list everywhere, and smaller bodies leave less room for error.
Glytec already sells the FDA-cleared Glucommander for adults, where technology-assisted titration has been shown to improve glucose control and cut hypoglycemia compared with manual paper protocols. A pediatric version would extend that approach into the NICU and PICU.
Chief executive Patrick Cua framed the gap plainly. Glucose is among the most frequently measured values in hospitals, he said, and newborns sit at the end of the problem where physiology is least stable and the available tools are fewest.
Breakthrough designation is not clearance. It grants a faster review path and closer FDA interaction, and it signals that regulators see a meaningful unmet need. Authorization still depends on clinical evidence in a population where trials are delicate to design and consent is difficult to obtain.
The designation also marks where pediatric software has trailed. Adult critical care tools have years of published evidence behind them, while the smallest patients, whose weight-based dosing is the trickiest to get right, have largely been left to paper protocols.
